

Transgenerational Effects in Mice Exposed to Continuous Low Dose-rate Gamma-rays  
– Analysis of Germ Cell Mutation –

Keiji OGURA, Katuyoshi FUJIKAWA, Ignacia TANAKA, Kazuaki ICHINOHE,  
Satoshi TANAKA, Jun-ichiro KOMURA  
*Department of Radiobiology*

Abstract

Transgenerational effects of continuous low dose-rate (LDR) gamma-rays irradiation of male mice have not been well studied. The incidence of copy number aberrations (CNAs) in the progeny of male C57BL/6J mice continuously exposed to LDR (20 mGy/22 h/day, 0.05mGy/22 h/day) gamma-rays for 400 days (total dose: 8000 mGy) was analyzed. Using oligo-microarray CGH (Agilent Technologies), we analyzed a total of 391 genomes (111 progenies from 20 pairs of parents in the 20 mGy/22 h/day irradiated group, 46 progenies from 6 pairs of parents in the 0.05 mGy/22 h/day irradiated group and 140 progenies from 20 pairs of parents in the non-irradiated group). Progeny from the 20 mGy/22 h/day irradiated mice had significantly higher frequencies of genomic aberrations than progeny from the non-irradiated mice. Mice containing more than five mutations were found only in the irradiated groups, whereas no such mice were found in the non-irradiated group. The F<sub>1</sub> mice with CNAs had the tendency to have a short life span in both the irradiated and non-irradiated groups.

Table 1 Number of mice and loci with aberrations

|                                       |       | No. of<br>F <sub>1</sub> mice<br>analyzed | No. of mice<br>with<br>aberrations | No. of loci<br>with<br>aberrations |
|---------------------------------------|-------|---|------------------------------------|------------------------------------|
| 20 mGy/ 22h/day<br>irradiated group   | ♀     | 48  | 10 (22.9 %)                        | 25 (Ave. 0.34 /generation)         |
|                                       | ♂     | 63  | 14 (22.2 %)                        | 150 (Ave. 2.38 /generation)        |
|                                       | ♀ + ♂ | 111                                       | 24 (22.5 %)                        | 175 (Ave. 1.58 /generation)        |
| 0.05 mGy/ 22h/day<br>irradiated group | ♀     | 21  | 2 ( 9.5 %)                         | 2 (Ave. 0.10 /generation)          |
|                                       | ♂     | 25  | 3 (12.0 %)                         | 41 (Ave. 1.64 /generation)         |
|                                       | ♀ + ♂ | 46  | 5 (10.8 %)                         | 43 (Ave. 0.93 /generation)         |
| Non irradiated<br>group               | ♀     | 73  | 9 (12.3 %)                         | 10 (Ave. 0.12 /generation)         |
|                                       | ♂     | 67  | 6 ( 9.0 %)                         | 12 (Ave. 0.18 /generation)         |
|                                       | ♀ + ♂ | 140                                       | 15 (10.7 %)                        | 22 (Ave. 0.16 /generation)         |

Table 2 Relationship between the presence of aberrations and life span in F<sub>1</sub> mice

|   | Aberrations | Life span<br>(day) | Cause of death  |  |                     |     |
|---|-------------|--------------------|-----------------|--|---------------------|-----|
|   |             |                    | Category        |  | Major               |     |
| 20 mGy/ 22h/day<br>irradiated group<br>(111 mice) | ♂           | Yes 13(20.6%)      | 794.8<br>±170.7 | Neoplasms 8 (66.6%)<br>Inflammation 1 (8.3%)<br>Others 3 (25.0%)     | Lymphoma, Malignant | 38% |
|   |             | No 50(79.3%)       | 843.7<br>±231.2 | Neoplasms 23 (48.9%)<br>Inflammation 13 (27.7%)<br>Others 11 (23.4%) | Lymphoma, Malignant | 14% |
|   | ♀           | Yes 11(22.9%)      | 706.1<br>±182.7 | Neoplasms 9 (81.8%)<br>Inflammation 1 (9.1%)<br>Others 1 (9.1%)      | Lymphoma, Malignant | 45% |
|   |             | No 37(77.1%)       | 799.8<br>±154.3 | Neoplasms 29 (78.4%)<br>Inflammation 4 (10.8%)<br>Others 4 (10.8%)   | Lymphoma, Malignant | 43% |
| non irradiated<br>group<br>(140 mice)             | ♂           | Yes 7(10.4%)       | 787.9<br>±340.5 | Neoplasms 3 (42.9%)<br>Inflammation 2 (28.6%)<br>Others 2 (28.6%)    | Lymphoma, Malignant | 14% |
|   |             | No 60(89.6%)       | 905.5<br>±172.2 | Neoplasms 34 (58.6%)<br>Inflammation 14 (24.1%)<br>Others 10 (17.2%) | Lymphoma, Malignant | 22% |
|   | ♀           | Yes 9(12.3%)       | 699.0<br>±167.0 | Neoplasms 7 (77.8%)<br>Inflammation 0 (0.0%)<br>Others 2 (22.2%)     | Lymphoma, Malignant | 67% |
|   |             | No 64(87.7%)       | 804.5<br>±158.5 | Neoplasms 43 (69.4%)<br>Inflammation 12 (19.4%)<br>Others 7 (11.2%)  | Lymphoma, Malignant | 41% |